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Acute tryptophan depletion (ATD) induces depressive 
symptoms in 50-60% of selective serotonin reuptake 
inhibitor (SSRI) treated, recovered depressed patients. 
However, no reliable predictors of mood response to ATD 
have been established. In the present study, individual 
subject data of six ATD studies were pooled (‘mega-
analysis’) in order to investigate the mediating role of 
clinical, demographic and biochemical characteristics in the 
mood response to ATD. A procedure was developed to make 
different versions of the Hamilton scale comparable. 
Recurrent depressive episodes, female gender, prior 
exposure to SSRI antidepressant treatment and previous 
serious suicidal thoughts/attempts all appear to be 
independent predictors of mood response to ATD. 
Chronicity of illness is the most powerful predictor. 
Residual symptoms of depression were not found to predict 
response to ATD. ATD may be useful to study the 
mechanism of action of SSRI antidepressants and 
individual biological vulnerability of the serotonin system. 
Whether the effects of ATD represent a reversal of the action 
of SSRI antidepressants or individual vulnerability 
probably depends upon the timing of the procedure in the 
course of remission of a depressive episode.
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Acute tryptophan depletion (ATD) is a technique used
to study serotonin (5-hydroxytryptamine; 5-HT) brain
function in mood disorders. In this paradigm, 5-HT
function is temporarily lowered by deprivation of its
precursor 
 
L
 
-Tryptophan (Trp), an amino acid essential
for 5-HT synthesis. It has been suggested that behav-
ioral response to ATD might be informative about the
pathophysiology of clinical depression and the mecha-
nisms mediating antidepressant efficacy.
A number of studies have demonstrated that ATD
temporarily induces depressive symptoms in remitted
depressive patients treated with antidepressant medi-
cation (Delgado et al. 1990; 1999; Spillman et al. 2001).
The recurrence of symptoms appears to be highest in
subjects treated with a selective serotonin reuptake in-
hibitor (SSRI) (Delgado et al. 1990, 1994, 1999).
However, not all patients react to ATD; even in SSRI-
treated patients, ATD exacerbates symptoms in 50–60%
of investigated patients (Van der Does 2001a). This
raises the question of what factors determine response
to ATD. It has been argued that induced depressive
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symptoms are limited to recently remitted, medicated
patients (Moore et al. 1998). However, clinically signifi-
cant symptom increases have been observed in unmed-
icated patients who were fully remitted for at least four
months (Smith et al. 1997). It has also been suggested
that depressed subjects with a history of suicidality are
more vulnerable to ATD (Leyton et al. 1997), but mood-
lowering effects have also been shown in patients with-
out a history of suicidal ideation (Neumeister et al.
1998). Other proposed factors are extent of depletion
(Spillman et al. 2001; Van der Does 2001a,b), quality of
response to medication and number of prior depressive
episodes (Spillman et al. 2001). Convincing evidence
has been found for none of these factors, possibly due
to the lack of statistical power.
A strategy to increase statistical power is ‘mega-anal-
ysis’ or ‘meta-analysis of original data’ (Olkin 1995). In
contrast to ‘traditional’ meta-analysis, in which the
‘unit’ of analyses is the study, in mega-analysis the data
from each subject are retained, allowing more sophisti-
cated analyses of the individual characteristics that
might mediate the effects. The present study used
mega-analysis to investigate the mediating role of clini-
cal, demographic and biochemical characteristics in the
mood response to ATD.
 
METHODS
Participants
 
The studies that were included in the reanalysis are
listed in Table 1. Eight research groups that had pub-
lished one or more ATD studies in remitted depressed
patients were approached. One research group did not
reply to three mailings. Another group accepted the in-
vitation to participate, but failed to provide data for six
months.
The total dataset consisted of 74 depressed patients
in remission. Results from patients with a primary di-
agnosis of bipolar disorder (n 
 

 
 3) were excluded, in or-
der to obtain a more homogeneous sample. The demo-
graphic and clinical characteristics of the remaining 71
subjects are shown in Table 2. All patients were either
free of antidepressant medication or were treated with
an SSRI at the time of taking part in the experiment.
In all studies, exclusion criteria were: (1) current or
past psychotic disorder; (2) a history of neurological or
endocrine disease; (3) pregnancy or lactation; (4) exces-
sive alcohol consumption; and (5) excessive dieting. Di-
agnoses had been made according to DSM-III-R or
DSM-IV criteria, using validated structured interviews.
Moore et al. (1998) included only males, whereas Smith
et al. (1997) included only females. All subjects had
given written informed consent.
 
Designs and Procedures
 
All studies had been conducted using a double-blind
cross-over design. In each study, the 
 
L
 
-tryptophan defi-
cient amino acid (AA) mixture had been made accord-
ing to the method used by Young et al. (1985). The
amount was reduced by about 20% on the basis of the
lower average weight of women in Smith et al. (1997)
and in Leyton et al.(1997, 2000). Two types of control
drinks were used. In Moore et al. (1998) and in Spillman
et al. (2001), the control drink consisted of a 25%
strength dose of the 
 
L
 
-tryptophan deficient mixture (25
g AA), following the procedure of Krahn et al. (1996). In
the other studies, the control drink contained the same
AA as the Trp deficient mixture plus 2.3 g/100 g 
 
L
 
-tryp-
tophan.
In each study, subjects arrived at the laboratory after
fasting overnight. Subjects were instructed to consume
the AA mixture within 2 h. Mood ratings and blood
 
Table 1.
 
Summary of Studies that Were Included in the Reanalysis.
 
References Site Sample characteristics Treatment Results 
 
Spillmann et al. 
(2001)
Boston, MA Major depression in clinical 
remission (n 
 

 
 10). 
SSRI Significant increase in HRSD-6 
scores. 6/10 relapsed after ATD.
Smith et al. (1997) Oxford, UK Major depressive episode,
fully remitted (n
 

 
 15). 
Females. 
Medication free. Prior 
treatment: SSRI, 
TCA or 
psychotherapy
Significant increase in HRSD-17 
scores. 5 patients full relapse; 5 
patients partial relapse.
Moore et al. (1998) San Diego, CA Major depressive episode,
fully remitted (n 
 

 
 10). 
Males.
SSRI Small increase in HRSD-24 scores, 
not clinically significant. 0/10 
relapsed after ATD.
Bremner et al. 
(1997)
New Haven, CT Major depression in clinical 
remission (n 
 

 
 21).
SSRI Small increase in HRSD-25 scores, 
not clinically significant. 7/21 
relapsed after ATD.
Leyton et al. 
(1997; 2000)
Montréal, Canada Major depressive episode,
fully remitted (n 
 

 
 18).
Medication free. Prior 
treatment: SSRI, 
TCA or 
psychotherapy
No effect on HRSD-17 scores 
(1997). Increase in HRSD-17 
scores (2000).
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samples were obtained prior to and 5–8 h after inges-
tion of the AA mixture. Medicated patients continued
their medication while participating in the study, in-
cluding the test days. Prior to each session, subjects
were kept on a low Trp diet for 12–24 h. The procedure
was repeated a couple of days later; subjects who had
received the Trp deficient mixture in the first session re-
ceived the control drink in the second session, and vice
versa.
 
Variables
 
Only variables recorded in at least two studies were
considered for inclusion in the reanalysis. All studies
had used the Hamilton Rating Scale for Depression
(HRSD) (Hamilton 1960) to assess mood changes, using
a 6, 17, 24 or 25 item version. Other included variables
were: free and total plasma Trp levels (% of reduction
after ingestion of the AA mixture relative to baseline),
gender, number of prior depressive episodes (based on
DSM criteria), duration of remission in months, type of
antidepressant treatment (SSRI vs. other), current anti-
depressant medication use (SSRI vs. no medication), re-
mission status (fully vs. partially remitted) and suicid-
ality (history of serious suicidal thoughts/attempts vs.
none). Type of antidepressant treatment implies the
type of treatment during the most recent episode. The
definition of remission was based on DSM-criteria, as
had been done in each of the original studies.
Duration of remission and number of prior depres-
sive episodes were assessed retrospectively in all stud-
ies, mostly by means of self-reported information and
medical records. This implies that these measures may
not be very reliable, particularly in subjects who had a
high number of previous episodes or who had been in
remission for a long time. For that reason, these vari-
ables were categorized. For chronicity of depression,
the sample was split into groups with a single episode
(n 
 

 
 18) and recurrent episodes (n 
 

 
 52). For duration
of remission, the split was at shorter (n 
 

 
 46) or longer
than 12 months remission (n 
 

 
 24).
 
Missing Data
 
Only change scores of the HRSD and plasma Trp levels
were available in the study by Bremner et al. (1997).
These patients could therefore not be included in linear
regression analyses. They were all taking SSRI medica-
tion at the time of the study. There were no differences
in terms of gender, depressive episodes or duration of
remission between this group and the patients included
in the regression analysis. Five patients in the pooled
dataset had no free and total Trp assessments in both
conditions. For two patients, total plasma Trp levels
could not be obtained in the control condition. For one
of these, free plasma Trp levels were also missing. Free
Trp levels were unavailable in the depletion condition
for one patient. One patient had a large increase in free
and total Trp levels (217% and 20%, respectively; no
data in the control condition). These values were con-
sidered coding errors and were excluded in the analy-
sis. For one patient, the mood ratings in the control con-
dition, the number of prior depressive episodes and
duration of remission were unavailable. Information
about type of antidepressant treatment was missing for
six patients.
 
Data Screening
 
Prior to analysis, data were screened for accuracy and
completeness by reconstructing published tables from
the datasets. The assumptions of linearity, normal dis-
tribution and homogenous variance were checked
graphically by means of residual plots (Weisberg 1985).
Outliers and influential data points were examined us-
ing Cook’s distance and Mahalonobis distances.
 
Computation of Statistically Comparable
Mood Scores
 
Since the HRSD versions were different in each study,
these scores had to be made statistically comparable. Al-
though a validation study demonstrated that different
versions of the HRSD are strongly correlated (O’Sullivan
et al. 1997), a closer look at their Table 2 (p. 382) makes
clear that there is no simple formula describing this rela-
tionship. For instance, a score of 5 on the HRSD-6 item
version is not necessarily equivalent to 20 on the 24 item
version. However, the relative rank of the HRSD scores
will be similar for the different item versions.
A statistical method to express the relative rank is
transformation of the original score into a Z-score. A
 
Table 2.
 
Demographic and Clinical Characteristics of the 
Subjects Included in the Pooled Dataset (n 
 

 
 71).
 
Variable Mean (SD)
 
Age (years) 39.1 (11.2)
Male (%) n 
 

 
 27(38%)
Number of prior depressive episodes 
(SD)
3.3 (3.5) (range: 1–40)
Duration of remission in months (SD) 18.8 (24.2) (range: 0–89)
SSRI treated n 
 

 
 54(76%)
TCA n 
 

 
 2(2.8%)
Psychotherapy n 
 

 
 5(7.0%)
Other medications n 
 

 
 1(1.4%)
Untreated n 
 

 
 3(4.2%)
Unknown n 
 

 
 6(8.4%)
Ongoing treatment (all SSRI) n 
 

 
 40 (56.3%)
Fully remitted n 
 

 
 40 (56.3%)
History of serious suicidal thoughts 
or attempts
n 
 

 
 17 (24%) 
(incomplete sample)
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Z-score expresses the deviation from the mean in stan-
dard deviation units, and emphasizes the relative posi-
tion of the score into a distribution (Hays 1988). Hence,
for each HRSD score in the dataset, a standardized
HRSD score is calculated by the formula: Z
 
it
 
 
 

 
 (X
 
itcj
 
 
 

 
M
 
bj
 
) / SD
 
bj
 
, where X
 
itcj
 
 is the score of subject 
 
i
 
 at time
point 
 
t
 
 (pre vs. post intervention) in condition 
 
c
 
 (ATD
 
vs.
 
 control testing) on HRSD version 
 
j
 
, 
 
M
 
bj
 
 is the mean
score at baseline (
 
t 
 

 
 0) on HRSD version 
 
j
 
, and SD
 
bj
 
 is
the standard deviation of HRSD version 
 
j
 
 at 
 
t
 
 
 

 
 . For in-
stance, the mean score at baseline on the HRSD-17 is 2.10
(SD 
 

 
 1.79). If a subject has a HRSD-17 score of 2 at
baseline and 18 after ATD, the Z-scores will be 
 

 
0.06 at
baseline and 8.88 after ATD.
In Spillman et al. (2001), Smith et al. (1997), and
Bremner et al.(1997), a clinically significant recurrence
in depressive symptoms after ATD (i.e. responder to
ATD: depressive ‘relapse’) was explicitly defined.
However, the definitions differed among studies. In or-
der to examine potential differences among criteria,
each criterion was expressed as a standardized score.
An additional criterion used by Delgado et al. (1990)
was also standardized, based on the mean and standard
deviation of the HRSD-25 scores before ATD described
in their Table 1 (p. 412). The standardized criteria were
applied to all subjects, implicating that five dichoto-
mous responder definitions (Smith et al. (1997) used
two definitions) were computed for each subject ac-
cording to five criteria.
 
Correlates and Predictors of Mood Effects of ATD
 
To assess the predictive power of clinical and demo-
graphic factors of mood response to ATD, hierarchical
multiple regression analyses were conducted. The de-
pendent variable was the change from baseline on the
ATD session (standardized post score minus standard-
ized pre score), minus the change from baseline after
control testing. Since there is convincing evidence that
the effect is highest in SSRI treated patients (Delgado et
al. 1990, 1999), the type of antidepressant treatment was
forced into the regression equation as the first predic-
tor. Next, the following variables were entered step-
wise: gender, number of prior depressive episodes, du-
ration of remission, current antidepressant medication
use, remission status, chronicity of illness (single epi-
sode vs. recurrent episodes) and duration of remission.
The relationship between mood response to ATD and
suicidality was analyzed by means of General Linear
Model (GLM) for repeated measures, using condition
(ATD vs. control testing) and time (pre vs. post inter-
vention) as within subjects factors and suicidality (at-
tempts/thoughts vs. none) as between subjects factors.
In order to correct for inflated probability of a type I
error and capitalizing on chance, more stringent criteria
were used. The semi-partial correlation of a predictor
with the dependent variable had to have a 
 
p-
 
value of
.01 or less to be entered into the regression equation
and its contribution was removed if the 
 
p
 
-value ex-
ceeded .05. Regression models were significant if the
 
p
 
-value was .05 or less. Group differences in change in
free and total plasma Trp levels were examined with
univariate GLM or nonparametric equivalents in case
of non-normal distribution of the data.
 
RESULTS
Biochemical Changes
 
Five to seven hours after depletion, free Trp levels were
reduced by 75.3% (SD: 20.5, range: 12.5%–100%) of their
initial value. In the control condition, the change in free
plasma Trp levels varied from an increase of 233% to a
reduction of 71.0% (mean: 24.6% (increase); SD: 69.9).
Total Trp was reduced by 76.7% (SD: 15.3; range 25.0%–
96.3%) in the ATD condition and varied in the control
condition from an increase of 137.4% to a reduction of
63.3% (mean: 10.2% (increase); SD: 44.3).
The percentage change of free and total Trp levels as
a function of gender and condition are shown in Table
3. The reduction in free plasma Trp levels was signifi-
cantly larger in females than in males after ATD (
 
z
 
 
 


 
3.50, 
 
df
 
 
 

 
 45, 
 
p
 
 
 

 
 .001). The reduction in total plasma
Trp levels following depletion also tended to be larger
in females, but this was not significant (
 
z
 
 
 

 
 
 

 
1.72, 
 
df
 
 
 

 
45, 
 
p
 
 
 

 
 .08). There were no gender differences in plasma
Trp levels in the control condition. No significant corre-
lation was found between the mood effects of ATD and
% change in total (
 
r
 
s
 
 
 

 
 
 

 
0.05, ns) or free plasma Trp
levels (
 
r
 
s
 
 
 

 
 0.08, ns).
 
Relapse Rate after ATD
 
Forty-six percent of the patients showed a clinically sig-
nificant increase of depressive symptoms after ATD,
based on the criteria of the individual studies. Smith et
al. (1997) used the most stringent definition of a re-
sponder to ATD (partial relapse: 44%). More liberal cri-
teria were used by Spillmann et al. (2001) and Bremner
et al. (1997) (both 52%). The relapse rate according to
the definitions of Delgado et al. was 46%. Hence, the
definitions used in the different studies are quite com-
parable, and lead to approximately 50% responders. A
full ‘relapse’, as defined by Smith et al. (1997), is ob-
served in one in five patients.
 
Correlates and Predictors of Mood Effects of ATD
 
Two subjects had a large Mahalonobis distance (
 

 
14)
and were considered multivariate outliers. These sub-
jects were left out of analysis. Results of the multiple re-
gression analyses are shown in Table 4. Type of prior
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antidepressant treatment, that was entered first, ac-
counted for 7.3% of the variance in the mood response.
This was not significant. When chronicity entered in the
equation, the unique contribution of type of antidepres-
sant treatment became significant, with total explained
variance 32.8%. The unique contribution of gender was
also significant and increased total explained variance
to 44.4%. Duration of remission, remission status, cur-
rent antidepressant medication use, and the actual
number of prior depressive episodes did not increase
total explained variance to a statistically significant de-
gree. The sign of the regression coefficients (
 
B
 
) indi-
cated that prior treatment with an SSRI, being female,
and chronicity predict a larger mood response to ATD.
Generalizability of the three predictor model was
evaluated by means of the leave-one-out procedure. N
multiple regression models were conducted, each using
N1 subjects. The mean multiple correlation coefficient
varied from 0.63 to 0.69 (mean 0.66; R2  0.43). Hence,
the differences between the values obtained with N1
subjects and the model described in Table 4 are quite
small, indicating that the model has good cross-validity
power. The effects of chronicity and gender as a func-
tion of intervention (ATD vs. control testing) and time
of assessment (pre vs. post intervention) are shown in
Figure 1 and 2, respectively.
Since women had a larger biochemical response to
ATD than men, the difference in mood response was
analyzed more carefully. The stepwise regression anal-
ysis was rerun (n  42), forcing type of prior antide-
pressant medication, gender, and chronicity, as well as
reduction in free Trp levels into the equation. The
unique contribution of chronicity and type of prior anti-
depressant medication remained significant (p  .01);
the contribution of gender was significant at p  .04,
though above our adjusted level of 0.01. The contribu-
tion of reduction in free Trp levels was not significant
(p  .71). The mood response did not correlate with
baseline severity of depression (r  0.23; ns).
Three studies contained information about the history
of suicidal ideation (Smith et al. 1997; Leyton et al. 1997,
2000). These studies used the HRSD-17. Two groups were
formed; a group without (n  17) and a group with a his-
tory of suicidal ideation (serious thoughts or one or more
suicide attempts) (n  13). Previously suicidal patients
had more depressive symptoms following ATD than sub-
jects without a history of suicidal thoughts or attempts (F
 11.44, df  1, 27, p  .02). Standardized HRSD scores
were calculated separately for patients who had serious
suicidal thoughts but had never shown suicidal behavior
(‘ideation’ group; n  7) and for patients with a history of
one or more suicide attempts (‘attempt’ group; n  6).
GLM analyses showed that the attempt group had signifi-
cantly more depressive symptoms following ATD than
subjects without any suicidal ideation (F  9.93; df  1, 20;
p  .005). The ‘ideation’ group had more depressive
symptoms than subjects with no suicidal ideation (F 
5.55; df  1, 21; p  .03). There were no significant differ-
ences between the ‘attempt’ group and the ‘ideation’
group (F  0.37, df  1, 11, p  ns). There were also no sig-
nificant group differences in the control condition. Effects
of condition for each subgroup are expressed in Figure 3.
DISCUSSION
The present ‘mega-analysis’ confirms that ATD elicits a
clinically significant recurrence of depressive symp-
Table 3. The Means (SD) of % Change in Plasma Trp Measures, Broken Down by “Gender” and “Condition (ATD vs. 
Control Testing)”. A Higher Score Corresponds With More Reduction after Ingestion of the AA Mixture.
ATD
Means (SD)
Control Testing
Means (SD)
Males Females Males Females
Free Trp (% reduction) 64.0 (20.5)
range: 12.5–93.4
81.5 (17.9)*
range: 25.4–100
35.05 (81.7)
range: 233.3–38.5
19.4 (64.0)
range: 170.6–71.0
Total Trp (% reduction) 72.4 (16.6)
range: 40.7–92.0
79.2 (14.1)
range: 25 –96.3
13.3 (40.7)
range:113.7–39.4
8.8 (46.4)
range: 137.4–63.3
* Significantly different from males (p  .001).
Table 4. Summary of the multiple regression analysis (n  44).
Step Variable Entered B  R2 change F change R2
1 Prior antidepressant treatment 2.72 0.44 0.07  3.00 0.07
2 History of prior depressive episodes  2.86  0.48 0.26 14.06** 0.33
3 Gender  1.98  0.36 0.12 7.49 * 0.44
* p  .01.
** p  .001.
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toms in approximately 50% of remitted depressed pa-
tients, whereas the control mixtures are inactive. A
smaller proportion, about 20%, fulfilled the criteria of a
‘full blown relapse’. The number of subjects that ful-
filled the more stringent criterion is also small in ATD
studies that were not included in the reanalysis. For in-
stance, although Delgado et al. (1990) reported a relapse
in 14 of 21 subjects (67%), converting their scores pro-
vided in Table 1 to standardized scores, shows that 3 of
21 patients had a full relapse (14%). This suggests that,
even in recently remitted patients, a clinical relapse is
uncommon (Moore et al. 2000). The general image
seems to be that ATD causes a complete or near return
of depression. However, an intermediary term, such as
‘partial relapse’ or ‘depressive exacerbation’ may be
more appropriate to describe the mood effects of ATD.
The strongest independent predictor of mood re-
sponse to ATD was chronicity (single vs. recurrent epi-
sodes). This suggests that there are differences in 5-HT
vulnerability between these groups of individuals.
Since the number of episodes was not associated with
more mood lowering effects to ATD this raises the pos-
sibility that dysregulation of the 5-HT system may oc-
cur after as few as two episodes.
The biological differences between subjects with a
single episode and those with recurrent episodes re-
quire further study. No ATD study has compared the
response to ATD in these two groups, but one study
presented data in sufficient detail to compare findings
for different types of patients. Delgado et al. (1990) re-
ported a relapse rate of 14 out of 21 depressed patients
in clinical remission. Visual inspection of their Table 1
(p. 412) reveals that only two of eight first-episode pa-
tients ‘relapsed’ after ATD (versus 12 of 13 patients
with more than one episode). Consequently, six of the
seven non-responders were first-episode patients.
These data are of particular interest because each
new episode increases the risk of chronicity (Keller et
al. 1992; Mueller et al. 1999). At present there is prelimi-
nary evidence that the mood response to ATD can pre-
dict a depressive episode one year after the challenge
(Moreno et al. 2000). Future studies may further investi-
gate the clinical significance of the mood response to
ATD with respect to outcome and prediction of risk for
recurrence, particularly in first-episode patients.
A significant difference in the magnitude of reduc-
tion in free Trp levels between males and females was
observed in the ATD condition. Similar, though not sta-
tistically significant, gender differences have been re-
ported in healthy individuals (Smith et al. 1997; Nish-
izawa et al. 1997). The lack of statistical significance
may reflect the smaller sample sizes, compared with the
present study.
Women also showed larger mood-lowering effects to
ATD than men. This larger mood-lowering effect in
women was not accounted for by the greater Trp deple-
tion nor by the investigated clinical characteristics, in-
cluding number of past episodes, duration of remission,
Figure 1. The means ( SE) of the HRSD (Z-scores), for
patients with single vs. recurrent episodes. A higher score
corresponds to more feelings of depression.
Figure 2. The means ( SE) of the HRSD (Z-scores) for
men and women. A higher score corresponds to more feel-
ings of depression.
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remission status, current SSRI treatment, past antide-
pressant treatment or suicidality.
The results of the present study are in accordance
with findings in healthy volunteers. ATD is more likely
to have mood-lowering effects (albeit small and sub-
clinical) in healthy women than men (Ellenbogen et al.
1996; Smith et al. 1997). A PET 	-[11C]methyl-L-tryp-
tophan study suggests that ATD leads to greater de-
creases in brain 5-HT synthesis in women than in men
(Nishizawa et al. 1997). Differences between healthy
men and women have also been observed in cere-
brospinal fluid (CSF) concentrations of 5-hydroxyin-
doleacetic acid (higher in women) (Agren et al. 1986),
neuroendocrine responses to 5-HT challenges (larger in
women) (Goodwinn et al. 1992) and 5-HT2 receptor
binding in several parts of the central nervous system
(CNS) (lower in women) (Biver et al. 1996). On the basis
of these studies, it can be concluded that, at least in
healthy subjects, there are gender differences in 5-HT
metabolism in the CNS and in the periphery. The gen-
der difference in mood response to ATD found in the
present study extends previous 5-HT challenge find-
ings in healthy samples.
The gender differences in mood response to ATD in
remitted depressed patients is also of interest in view of
a recent finding that women may respond to the SSRI
sertraline more often than men, whereas men may re-
spond more favorably to the tricyclic antidepressant
imipramine (Kornstein et al. 2000). Evidence exists that
estrogen hormones facilitate 5-HT receptor sensitivity
(Joffe and Cohen 1998). Hormonal factors may play a
role in gender differences in 5-HT brain function and in
risk and treatment outcome of depression.
The unique contribution of gender did not reach the
significance level of 1% after the greater lowering of
free Trp in women was controlled for, but the effect was
not eliminated (p  .04). This suggests that the greater
sensitivity of recovered depressed women to ATD may
reflect a greater impairment of 5-HT function. Future
studies should further explore the relationship between
magnitude of reduction of Trp, mood, and gender.
As expected, type of antidepressant treatment pre-
dicted response to ATD. Subjects who had received an
SSRI showed larger mood responses than patients who
had been treated otherwise. However, current antide-
pressant (SSRI) treatment was not associated with a
larger mood effect. This contrasts with previous reports
that patients currently being treated with SSRIs are par-
ticularly vulnerable to mood-lowering effects following
ATD (Delgado et al. 1990); however, this might reflect a
difference between recently remitted patients and those
who have been in remission for over 18 months.
Mood-lowering effects of ATD were more pro-
nounced in patients with a history of suicidal thoughts
or attempts. The data suggest that the 5-HT system may
be more disturbed in depressed individuals with sui-
cidal tendencies than in those without (Leyton et al.
1997, 2000).
The influence of suicidality on mood response to
ATD may reflect differences in impulse control or high
inward-aggression levels. This notion is supported by
the behavioral effects of ATD found in subjects who
have an increased risk for developing disorders that are
characterized by impulsive behaviors, including ag-
gression (Cleare et al. 1995; Pihl et al. 1995), substance
abuse (LeMarquand et al. 1995) and bulimia nervosa
(Weltzin et al. 1995; Smith et al. 1999).
Some evidence suggests that abnormalities of the
5-HT system may be limited to a subtype of depression;
i.e. those in which anxiety and aggression dysregula-
tion are the primary dysfunctions (Van Praag 1991,
1996). A subgroup of depressed patients with instabil-
ity of aggression regulation may be particularly prone
to the mood-lowering effects of ATD. It is noteworthy
that all data of the subjects that had a history of serious
suicidal thoughts or attempts in the patients were from
fully remitted patients. This indicates that the possible
underlying disturbed aggression regulation related to
abnormalities in 5-HT brain function may be a trait
characteristic, rather than an expression of symptoms
(Van Praag 1991).
Some limitations deserve attention. First, the vari-
able ‘history of suicidal ideation’ was assessed retro-
spectively and based on self-reported information. This
implies that classification may be difficult. On the other
Figure 3. The means ( SE) of the HRSD (Z-scores) as a
function of history of suicidality. Values are expressed as
change from baseline. A higher score corresponds to more
feelings of depression.
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hand, the distinction between “one or more attempts”
and “no history of suicidal ideation” is probably reli-
able. Information about suicidality was only available
for a subset of the dataset, precluding it from being en-
tered into the regression equation. However, the ab-
sence of an association between suicidality and the
other patient characteristics examined suggests that sui-
cidality is an independent predictor. No ATD experi-
ments were found that focused explicitly on the rela-
tionship between suicidality and the mood response to
ATD. The present results suggest that future studies
should gather more detailed information about the his-
tory of suicidal tendencies (Leyton et al. 1997).
Tryptophan Depletion as a Model of SSRI 
Antidepressant Mechanisms vs. Individual 
Biological Vulnerability
The present study did not support a number of previ-
ously suggested associations. Duration of remission
was not associated with the mood response to ATD.
Also, differences between partial and fully remitted pa-
tients were far from significant. It should be noted how-
ever that the latter variable, as well as the variable ‘cur-
rent antidepressant medication use’ were nested within
individual studies, making these variables less appro-
priate for the present reanalysis. An alternative expla-
nation for the finding that current use of antidepres-
sants does not predict response to ATD may be a
methodological one; this variable probably correlates
highly with prior use of SSRIs (which is a significant
predictor) and with chronicity (as patients with recur-
rent episodes are typically kept on antidepressants),
and may not present enough spread (as many investi-
gators tended to recruit patients on SSRIs for this chal-
lenge) to detect the effect of current treatment.
One major difference with Delgado et al. (1990, 1999)
is that 69 of the 71 patients included in this reanalysis
had shown improvement for at least one month (mean:
18.3 months). In contrast, subjects enrolled in the Del-
gado studies were clinically stable for only two to four
weeks and were on antidepressant medication not
longer than 10 weeks. Possibly, if applied soon after the
onset of treatment response, ATD interferes with the ac-
tion of SSRIs (Moore et al. 1998). The present study sug-
gests that this dependency may be restricted to only the
first few weeks after starting antidepressant treatment.
Once the therapeutic effect has been reached, a mood-
lowering response to ATD may reflect individual bio-
logical vulnerability of the 5-HT system, rather than
mechanism of antidepressant action.
Methodological Considerations
A methodological point of concern is the method of
pooling data of individual studies itself. It has been
suggested that pooling individual subject data provides
the most valid and reliable way of addressing research
questions that cannot be adequately resolved by indi-
vidual studies (Stewart et al. 1993). It has the advantage
of a more detailed data-analysis and increased statisti-
cal power. In contrast to traditional meta-analysis, indi-
vidual subject characteristics are retained, allowing a
more sensitive analysis. Despite these advantages, a
limitation is that the reliability and validity of the
present study is dependent on the reliability and valid-
ity of the individual studies (Wolf 1986). Combining in-
formation from different studies assumes that the stud-
ies are uniform enough to pool them. To investigate this
potential bias, a leave-one-out procedure was con-
ducted, which showed that the predictors have good
cross-validity power. Moreover, all predictors were pa-
tient characteristics that varied within studies, rather
than nested characteristics of the individual studies.
Also, all diagnoses and assessments were conducted ac-
cording to standardized, reliable methods. Therefore, it
is unlikely that the effect of the three-predictor model is
mediated by a confounding variable such as study site.
Some further issues deserve attention. First, we
could not include the data from all investigators who
have published ATD studies. Second, we could not in-
clude all 71 available subjects in the regression analysis.
On the other hand, 15 subjects per predictor is usually
sufficient for a reliable regression equation, one that
will cross-validate well (Stevens 1996). Third, several
other clinical variables that could not be included may
mediate the mood response to ATD, e.g. duration of
treatment, time-off medications and other types of pre-
vious treatment, (e.g., tricyclic antidepressants [TCAs],
monoamine oxidase inhibitors [MAOIs], electroconvul-
sive therapy [ECT], and psychotherapy).
An additional issue concerns the different HRSD ver-
sions. The present study has illustrated a way to make
different item versions comparable if only total scores
rather than individual item scores are available. Previous
research has shown that the 6, 17, and 24-item versions
are highly positively correlated before and after pharma-
cological treatment, indicating that different item ver-
sions are of comparable sensitivity to detect changes in
depressive symptomatology over time (O’Sullivan et al.
1997). The notion of a positive correlation between the
different HRSD versions may appear self-evident, but it
is important, since it implies that the relative rank of the
scores is similar across different scale versions. This
property justified the standardization procedure that
made these versions directly comparable. Considering
the widespread use of the HRSD and the many different
versions that exist, the standardization procedure de-
scribed here may be useful to other researchers wishing
to combine results from different studies.
In conclusion, this reanalysis shows that recurrent
depressive episodes, female gender, treatment with an
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SSRI and history of suicidal thoughts/attempts are pre-
dictive of a mood-lowering response to ATD. Together,
the results suggest that mood-lowering responses to
ATD might be informative for two purposes: (1) identi-
fying serotonergic mechanisms of antidepressant effi-
cacy; and (2) identifying 5-HT related differences in bio-
logical vulnerability to depression.
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